Through the transaction, Aurobindo USA will expand its product portfolio in this segment while gaining a U.S.-based manufacturing facility
The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
Revenue increased 11.4 per cent to Rs. 8,545 crore
Subscribe To Our Newsletter & Stay Updated
